doi: 10.1016/j.ijgfs.2023.100676 30
"The big surprise is why the BMJ accepted the study in the first place," says Marion Nestle, professor emerita of nutrition and food studies at New York University
The Endocrine Society's 2023 guideline states: "For adults with obesity and established cardiovascular disease, clinicians should offer semaglutide 2.4 mg subcutaneous weekly as an adjunct to lifestyle intervention to reduce cardiovascular morbidity and mortality" [8]
Published BPC-157 studies have generated a preclinical literature base spanning gastrointestinal cytoprotection, vascular recruitment, angiogenesis-associated signaling, fibroblast migration, tendon-cell biology, and central nervous system research models
From cardiovascular support to mental clarity to muscle maintenance, the benefits go well beyond the scale
Slow titration helps: Starting low and stepping up gradually reduces early GI events [1]